Reuters - U.S. regulators should halt their review of Eli Lilly and Co's bloodthinner candidate prasugrel, a U.S. advocacy group and one of the drug's early researchers said on Wednesday, citing concerns over the dose tested in a major study.
Reuters - U.S. regulators should halt their review of Eli Lilly and Co's bloodthinner candidate prasugrel, a U.S. advocacy group and one of the drug's early researchers said on Wednesday, citing concerns over the dose tested in a major study.
